17th World ADC San Diego | October 12-15, 2026

Returning as the largest and most definitive ADC congress, the 17th World ADC San Diego is the one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends, and networking opportunities to drive ADC innovation toward differentiated, early-line patient outcomes.

With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply, all aspects of ADC innovation will be in the spotlight during an unmissable week of data and insights to de-risk future ADC development and advance ADCs into earlier-line oncology treatments.

Explore the full 4-day experience here: https://ter.li/y19qemt6

Uniting 1,300 senior industry leaders from biopharma, innovative start-ups, leading service providers, and academic, physician, and regulatory KOLs, World ADC San Diego is the place to discuss, debate, and advance the future of ADC development.

New Industry-Leading Insights in 2026

Center-Stage MoA, Targeting & Design Innovation to Advance Differentiated & Impactful ADC Therapies
Committed to maintaining its position at the forefront of ADC R&D and design, the 2026 program has been enriched with discovery and translational insights across novel cytotoxic MoAs, including pan-PI3K/mTOR inhibitors, protein alkylation, antifolate ADCs, and translation inhibitors, as well as DACs, ISACs, AOCs, bsADCs, dpADCs, and conditionally active ADCs.

An Increasing Forum of Choice for Exclusive, First-Time ADC Data & Research Disclosures
PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency | AstraZeneca
Spotlighting the Translational Profile of KIVU-107 to Strive for Kinder & Gentler ADC Therapies with an Enhanced Therapeutic Index | Kivu Bioscience

Brand-New Companies Making Their World ADC Debut
Committed to showcasing continually refreshed and alternative perspectives on ADC development, hear from first-time presenting companies Callio Therapeutics, Canwell Pharma, Immunome, MediLink Therapeutics, NEOK Bio, Solve Therapeutics, and XYone Therapeutics.

Upgraded Clinical Content to Unlock ADC Differentiation
Leverage enhanced biopharma and ADC physician perspectives to better navigate crowded and underserved clinical indications to achieve ADC differentiation and improved patient outcomes:

Evaluating I-SPY2 clinical data & toxicity monitoring to assess ADC progression into early-stage oncology settings in TNBC & HER2+ breast cancer | University of Chicago
Exploring “ADC + Antibody” as an emerging combination strategy for solid tumor therapies | Hangzhou Institute of Medicine

View and download the agenda here to start building your personalized World ADC San Diego experience: https://ter.li/y19qemt6